AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
Jul 23, 2021
31637_dirs_2021-07-23_367a160e-bff3-40b9-b854-86a9cb85882e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-07-21
Reporting Person: SATO VICKI L (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-07-21 | Common Stock | S | 400 | $64.25 | Disposed | 134097 | Direct |
| 2021-07-21 | Common Stock | S | 866 | $65.24 | Disposed | 133231 | Direct |
| 2021-07-21 | Common Stock | S | 400 | $65.78 | Disposed | 132831 | Direct |
Footnotes
F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $63.60 to $64.59 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: Includes 2,074 restricted stock units.
F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $64.61 to $65.59 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $65.63 to $66.06 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.